Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 3rd Floor Bellevue Centre,, 235-15th Str WEST VANCOUVER BC V7T 2X1 |
Tel: | N/A |
Website: | https://briacell.com |
IR: | See website |
Key People | ||
William V. Williams President, Chief Executive Officer, Director | Gadi Levin Chief Financial Officer, Corporate Secretary | Miguel A. Lopez-Lago Chief Scientific Officer | Giuseppe Del Priore Chief Medical Officer |
Business Overview |
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company's lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient's own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte's immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient's HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers. |
Financial Overview |
For the six months ended 31 January 2024, Briacell Therapeutics Corp revenues was not reported. Net loss decreased 59% to $5.3M. Lower net loss reflects Change in fair value of warrant liabilit increase from $3.5M (expense) to $12.7M (income), General and administrative expenses decrease of 10% to $3.2M (expense), Foreign exchange gain (loss) decrease of 32% to $11K (expense). |
Employees: | 5 as of Jul 31, 2020 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $18.00M as of Jan 31, 2024 |
Annual revenue (TTM): | $0.00M as of Jan 31, 2024 |
EBITDA (TTM): | -$43.65M as of Jan 31, 2024 |
Net annual income (TTM): | -$17.36M as of Jan 31, 2024 |
Free cash flow (TTM): | -$43.04M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 15,981,726 as of Mar 18, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |